Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and < em > IDH1/2 < /em > mutation: a network meta-analysis

In conclusion, venetoclax plus azacitidine could be a good option for unfit newly diagnosed patients with acute myeloid leukemia and IDH1/2 mutation. Considering our limits (only trial data-based network meta-analysis et al.), future trials directly comparing these regimens are warranted.PMID:37599456 | DOI:10.1080/1120009X.2023.2247200
Source: Journal of Chemotherapy - Category: Cancer & Oncology Authors: Source Type: research